Alterman AI et al. (2001). Short- and long-term smoking cessation for three levels of intensity of behavioral treatment. Psychology of Addictive Behaviours, 15, 261-264.

Bane CM et al. (1999). Development of a pregnancy-tailored decisional balance measure for smoking cessation. Addictive Behaviors, 24, 795-799.

Bannon YB et al. (1989). Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. European Journal of Clinical Pharmacology, 37, 285-290.

Benowitz NL et al. (1998). Suppression of nicotine intake during ad libitum smoking by high-dose transdermal nicotine. Journal of Pharmacology and Experimental Therapeutics, 287, 958-962.

Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, Comings DE. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 1996;89(7):396-400.

Cinciripini PM et al. (1994). An evaluation of a multicomponent treatment program involving scheduled smoking and relapse prevention procedures: initial findings. Addictive Behaviors, 19, 13-22.

Cinciripini PM et al. (1996). Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping. Journal of Consulting and Clinical Psychology, 64, 314-323.

Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996;6(1):73-9.

Cornuz J et al. (1997). Smoking cessation counseling by residents in an outpatient clinic. Preventive Medicine, 26, 292-296.

Cutler, C., Preventative medicine in managed care, JUNE 25, 2002, VOL. 3, NO. 3

Dale LC et al. (1995). High-dose nicotine patch therapy: percentage of replacement and smoking cessation. Journal of the American Medical Association, 274, 1353-1358.

Dijkstra A & De Vries H (1999). The development of computer-generated tailored interventions. Patient Education and Counseling, 36, 193-203.

Dijkstra A et al. (1999). Targeting smokers with low readiness to change with tailored and nontailored self-help materials. Preventive Medicine, 28, 203-211.

Etter JF & Perneger TV (2001). Effectiveness of a computer-tailored smoking cessation program: a randomized trial. Archives of Internal Medicine, 161, 2596-2601.

Farvolden, P and Mierlo, T, (2003). Web-based collaborative disease management and health behaviour change [Available at http://www.v-cc.com/research/]

Fortmann SP & Killen JD (1995). Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment. Journal of Consulting and Clinical Psychology, 63, 460-468.

Fournier, R., (2004). NRT and Buproprian usage amoung users of a web-based smoking cessation support group [Available from: http://www.v-cc.com/research/]

Fredrickson PA et al. (1995). High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology, 122, 215-222.

Gorsline J et al. (1991). Nicotine dose relationship for Nicoderm at steady state. Pharmaceutical Research, 10, S299.

Haberl, M., Et Al, (2005). Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenetics and Genomics 2005, 15:609–624

Hall SM et al. (1994). Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. Journal of Consulting and Clinical Psychology, 62, 141-146.

Hughes JR et al. (1990). Effect of dose on nicotines reinforcing, withdrawal-suppression and self-reported effects. Journal of Pharmacology and Experimental Therapeutics, 252, 1175-1183.

Hurt RD et al. (1993). Serum nicotine and cotinine levels during patch therapy. Clinical Pharmacology and Therapeutics, 54, 98-106.

Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;14(2):83-90.

Johnstone, E., et.al. Nicotine & Tobacco Research 2004; (2):377-379.

Johnstone,E.,Benowitz,N.,Cargill,A.,Jacob,R.,Hinks,L.,Day,I.,Murphy,M.,Walton,R. (2006). Determinants of the rate of nicotine metabolism and effects on smoking behaviour. Clinical Pharmacology & Therapeutics  80:319–330.

Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999;4(3):290-6.

Jorenby DE et al. (1995). Varying nicotine patch dose and type of smoking cessation counseling. Journal of the American Medical Association, 274, 1347-1352.

Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev 2002(3):CD001118.

Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH, Jr., Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003;22(5):541-8.

Lerman et al. (2002). Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics, 12, 627-634.

Lifrak P et al. (1997). Results of two levels of adjunctive treatment used with the nicotine patch. American Journal of Addiction, 6, 93-98.

Marlow SP & Stoller JK (2003). Smoking cessation. Respiratory Care, 48, 1238-1254.

McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D, Murphy M, Welsh KI, Marshall SE. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 2000;10(6):483-91.

Mermelstein R et al. (2003). Extended telephone counseling for smoking cessation: does content matter? Journal of Consulting and Clinical Psychology, 71, 565-574.

Miller NH et al. (1997). Smoking cessation in hospitalized patients. Results of a randomized trial. Archives of Internal Medicine, 157, 409-415.

Mogielnicki RP et al. (1986). Tailored media can enhance the success of smoking cessation clinics. Journal of Behavioral Medicine, 9, 141-161.

Munafò et al. (2004). The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine and Tobacco Research, 6, 583-597.

Munafo M, Johnstone E, Murphy M, Walton R. New directions in the genetic mechanisms underlying nicotine addiction. Addict Biol 2001;6(2):109-117.

Munafo' M, Johnstone E, Welsh K, Walton R. Association between the DRD2 gene TAq1A polymorphism and alcohol consumption in social drinkers (in press). The Pharmacogenomics Journal 2004.

Munafo MR, Clark TG, Moore LR, Payne E, Walton R, Flint J. Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis. Mol Psychiatry 2003;8(5):471-84.

Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004;23(6):540-5.

Noble EP, St. Jeor ST, Ritchie T, Syndulko K, St. Jeor SC, Fitch RJ, Brunner RL, Sparkes RS. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 1994;42(4):257-60.

Orleans CT & Fishman J (2000). Tailored communications for smoking cessation. Introduction. Tobacco Control, 9, I49.

Orleans CT et al. (2000). Computer tailored intervention for older smokers using transdermal nicotine. Tobacco Control. 9, I53.

Owens N et al. (1989). Smoking cessation by mail: a comparison of standard and personalized correspondence course formats. Addictive Behaviors, 14, 355-363.

Reid RD et al. (1999). Is telephone counselling a useful addition to physician advice and nicotine replacement therapy in helping patients to stop smoking? A randomized controlled trial. Canadian Medical Association Journal, 160, 1577-1581.

Rimer BK & Orleans CT (1994). Tailoring smoking cessation for older adults. Cancer, 74, 2051-2054.

Secker-Walker RH et al. (1994). Individualized smoking cessation counseling during prenatal and early postnatal care. American Journal of Obstetrics and Gynecology, 171, 1347-1355.

Strecher VJ (1999). Computer-tailored smoking cessation materials: a review and discussion. Patient Education and Counseling, 36, 107-117.

Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, Curry SJ, McAfee T. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2004.

Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997;7(6):479-84.

Tonnesen P et al. (1999). Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE study. European Respiratory Journal, 13, 238-246.

Walton R, Dovey S, Harvey E, Freemantle N. Computer support for determining drug dose: systematic review and meta- analysis BMJ 1999;318(7189):984-90.

Walton RT, Harvey E, Dovey S, Freemantle N. Computerised advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 2001(1):CD002894.

Walton 2006 paper : Drugs and genotypes: how pharmacogenetic information could improve smoking. Lee and Tyndale J Psychopharmacol.2006; 20: 7-14

Walton, RW et al (2001). Computerised advice on drug dosage to improve prescribing practice. The Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.:002894. DOI: 10.1002/14651858.CD00894

Wright LN (1996). Statewide assessment of a behavioral intervention to reduce cigarette smoking by pregnant women. American Journal of Obstetrics and Gynecology, 175, 283-287

Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990;29(5):1322-9.

Yudkin P, Munafo M, Hey K, Roberts S, Welch S, Johnstone E, Murphy M, Griffiths S, Walton R. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 2004;328(7446):989-90.

Zabetian, C. P.; Anderson, G. M.; Buxbaum, S. G.; Elston, R. C.; Ichinose, H.; Nagatsu, T.; Kim, K.-S.; Kim, C.-H.; Malison, R. T.; Gelernter, J.; Cubells, J. F.(2001). A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am. J. Hum. Genet. 68: 515-522, 2001. PubMed ID : 11170900.

< Prev		Next >